We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Non-Invasive Fecal DNA Test Accurately Detects Colorectal Cancer and Precancerous Lesions

By LabMedica International staff writers
Posted on 30 Mar 2023
Print article
Image: COLOTECT 1.0 can help improve colorectal cancer prevention and early detection (Photo courtesy of BGI)
Image: COLOTECT 1.0 can help improve colorectal cancer prevention and early detection (Photo courtesy of BGI)

Colorectal cancer is a highly prevalent form of cancer worldwide, with over 1.9 million new cases reported in 2020, and is a leading cause of cancer-related deaths. Fortunately, regular screening can help prevent many cases of colorectal cancer. Common screening methods include both invasive procedures like flexible sigmoidoscopy and colonoscopy, as well as non-invasive options such as blood tests and fecal-based tests. Currently, fecal-based tests available include the guaiac-based fecal occult blood test (gFOBT), fecal immunochemical test (FIT), and the new, multitarget stool DNA test.

The newer fecal DNA testing, being able to detect specific DNA changes found in cancerous tumors or precancerous polyps, is generally considered more sensitive than FIT. Aberrant DNA methylation is an early molecular change that is common, stable, and detectable in small amounts of DNA during carcinogenesis. Consequently, cells from precancerous and cancerous lesions with these mutations are often shed as DNA biomarkers into the stool. Thus, fecal DNA testing has the potential to outperform FIT not only in detecting colorectal cancer but, more significantly, in detecting precancerous adenoma.

BGI Genomics (Shenzhen, China) has developed a non-invasive fecal DNA test, known as COLOTECTTM 1.0, to detect colorectal cancer and precancerous lesions. The test employs multiplex methylation-specific PCR (MSP) technology to track abnormal DNA-methylation biomarkers in stool samples. Detection of methylated DNA as a tumor biomarker has become common in several cancer types, including colorectal cancer. The COLOTECTTM 1.0 is highly sensitive and specific, with a straightforward workflow approach and compatible with commonly used PCR platforms. The test has a 88% sensitivity for colorectal cancer and a remarkable 46% sensitivity for detecting advanced adenoma for early detection. Additionally, its specificity for non-advanced neoplasms is as high as 92%.

In case of abnormal results detected by the COLOTECT 1.0 test, patients will require additional diagnostic tests and consultations with a medical professional. The test's non-invasive and easy-to-use characteristics make it easier for patients to overcome barriers to colorectal screening. COLOTECT 1.0 has the potential to enhance colorectal cancer prevention and early detection, providing patients with better health outcomes and improved convenience. The test is CE-marked and currently available in over 20 countries in South-East Europe.

Related Links:
BGI Genomics

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: A false color scanning election micrograph of lung cancer cells grown in culture (Photo courtesy of Anne Weston)

AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell

Current strategies for matching cancer patients with specific treatments often depend on bulk sequencing of tumor DNA and RNA, which provides an average profile from all cells within a tumor sample.... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.